CARF (Collaborator of ARF) overexpression in p53‐deficient cells promotes carcinogenesis

[1]  Charles Swanton,et al.  Tumour heterogeneity and the evolution of polyclonal drug resistance , 2014, Molecular oncology.

[2]  Rumani Singh,et al.  Collaborator of ARF (CARF) Regulates Proliferative Fate of Human Cells by Dose-dependent Regulation of DNA Damage Signaling* , 2014, The Journal of Biological Chemistry.

[3]  L. Attardi,et al.  Unravelling mechanisms of p53-mediated tumour suppression , 2014, Nature Reviews Cancer.

[4]  R. Reddel,et al.  Molecular characterization of collaborator of ARF (CARF) as a DNA damage response and cell cycle checkpoint regulatory protein. , 2014, Experimental cell research.

[5]  G. Ferbeyre,et al.  Complete senescence , 2014, Cell cycle.

[6]  B. Pützer,et al.  E2F1 apoptosis counterattacked: evil strikes back. , 2013, Trends in molecular medicine.

[7]  R. Sachidanandam,et al.  A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis , 2013, Cell Death and Differentiation.

[8]  Sheng Lin,et al.  Autocrine CCL5 Signaling Promotes Invasion and Migration of CD133+ Ovarian Cancer Stem‐Like Cells via NF‐κB‐Mediated MMP‐9 Upregulation , 2012, Stem cells.

[9]  Z. Kiliańska,et al.  Puma, a critical mediator of cell death — one decade on from its discovery , 2012, Cellular & Molecular Biology Letters.

[10]  A. Erol.  Deciphering the intricate regulatory mechanisms for the cellular choice between cell repair, apoptosis or senescence in response to damaging signals. , 2011, Cellular signalling.

[11]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[12]  S. Kaul,et al.  Molecular characterization of apoptosis induced by CARF silencing in human cancer cells , 2011, Cell Death and Differentiation.

[13]  Y. Toiyama,et al.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer , 2010, British Journal of Cancer.

[14]  Y. Okada,et al.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1–PI3K–Rac1 pathway , 2010, British Journal of Cancer.

[15]  Carlos Caldas,et al.  Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary , 2010, The Journal of pathology.

[16]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[17]  B. Pützer,et al.  E2F1 in melanoma progression and metastasis. , 2010, Journal of the National Cancer Institute.

[18]  Navjot Shah,et al.  CARF Is a Vital Dual Regulator of Cellular Senescence and Apoptosis* , 2009, Journal of Biological Chemistry.

[19]  T. Hirano,et al.  CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway. , 2008, International journal of oncology.

[20]  J. Bartek,et al.  DNA damage signalling guards against activated oncogenes and tumour progression , 2007, Oncogene.

[21]  Markus F Templin,et al.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. , 2005, Clinical chemistry.

[22]  J. Campisi.  Senescent Cells, Tumor Suppression, and Organismal Aging: Good Citizens, Bad Neighbors , 2005, Cell.

[23]  N. Jones,et al.  Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53 , 2005, The Journal of cell biology.

[24]  T. Hirano,et al.  Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control. , 2004, The Biochemical journal.

[25]  Yupo Ma,et al.  p150Sal2 Is a p53-Independent Regulator of p21WAF1/CIP , 2004, Molecular and Cellular Biology.

[26]  B. Wiedenmann,et al.  Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. , 2002, Journal of the National Cancer Institute.

[27]  Goberdhan P Dimri,et al.  Regulation of a Senescence Checkpoint Response by the E2F1 Transcription Factor and p14ARF Tumor Suppressor , 2000, Molecular and Cellular Biology.

[28]  M. Herlyn,et al.  Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  N. Krucher,et al.  Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities , 1998, Oncogene.

[30]  S. Groshen,et al.  Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. , 1998, Cancer research.

[31]  H Nagahara,et al.  Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[33]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[34]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[35]  B. Pützer,et al.  hyperphosphory-E2F1 in Melanoma Progression and Metastasis , 2010 .

[36]  N. Jones,et al.  Reduction of total E 2 F / DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p 53 , 2005 .